The nepexto market research report is one of a series of new reports that provides nepexto market statistics, including nepexto industry global market size, regional shares, competitors with a nepexto market share, detailed nepexto market segments, market trends and opportunities, and any further data you may need to thrive in the nepexto industry. This nepexto market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to increasing demand for cost-effective biologics alternatives, expansion of biosimilar markets in developing regions, supportive regulatory frameworks for biosimilar adoption, rising healthcare expenditure globally, growing preference for homecare and self-administered biologics. Major trends in the forecast period include a shift toward personalized medicine in biologics, growth of digital marketing and education for biosimilars, adoption of advanced drug delivery systems for biosimilars, strategic collaborations and partnerships in biosimilar development, and technological advancements in biologics manufacturing.
The growing prevalence of chronic diseases is expected to drive the expansion of the nepexto market. Chronic diseases are long-term conditions that typically last for more than three months and may require continuous medical attention or limit daily activities. The rise in chronic diseases can be attributed to factors such as aging populations, unhealthy lifestyles, and advancements in medical care, which help people with acute conditions live longer and, consequently, increase the occurrence of long-term health issues. Nepexto is used to treat chronic autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis, offering a cost-effective and accessible solution for managing these conditions over time. For example, in February 2024, the Centers for Disease Control and Prevention (CDC) reported that the prevalence of diagnosed arthritis in adults aged 18 and older was 18.9% in 2022, with women (21.5%) experiencing a higher incidence than men (16.1%). The prevalence of arthritis rises with age, from 3.6% in individuals aged 18-34 to 53.9% in those aged 75 and older. This increasing prevalence of chronic diseases is expected to support the growth of the nepexto market.
The rise in healthcare expenditure is anticipated to fuel the growth of the nepexto market. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including personal health care, preventive services, and public health activities aimed at improving health outcomes. This spending is increasing due to factors such as an aging population, chronic diseases, advancements in medical technology, high drug prices, inefficient payment models, and rising demand for healthcare services. Nepexto benefits from this increase in healthcare expenditure by providing a cost-effective treatment option for chronic autoimmune diseases, helping manage resource allocation while ensuring that patients have access to advanced biologic therapies. For example, in May 2024, the Office for National Statistics reported that healthcare expenditure in the UK rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Furthermore, long-term health and social care spending increased by 2.8% in real terms in 2022. As a result, rising healthcare expenditure is expected to drive the growth of the nepexto market.
A notable trend in the nepexto market is the development of biosimilars, such as etanercept, which are expected to provide a competitive advantage in the industry. Etanercept biosimilars are biological medications designed to replicate the original etanercept's structure, function, and therapeutic effects, often used to treat autoimmune conditions. For example, in May 2024, Lupin, an India-based pharmaceutical company, partnered with Sandoz, a Switzerland-based pharmaceutical company, to launch Rymti, an etanercept biosimilar, in Canada. The introduction of Rymti is expected to improve treatment options for patients with chronic inflammatory diseases while contributing to more sustainable healthcare solutions by providing a cost-effective alternative to existing therapies.
The key company operating in the nepexto market is Lupin Limited.
Europe was the largest region in the nepexto market in 2024. The regions covered in nepexto report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nepexto market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Nepexto is a biosimilar medication designed as an alternative treatment option for patients with autoimmune diseases. It is developed to closely match the reference biologic in terms of safety, efficacy, and quality. Nepexto is commonly used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, providing patients with a cost-effective and accessible therapeutic choice.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Nepexto include growth hormone deficiency, short stature due to idiopathic causes, Turner syndrome, and Prader-Willi syndrome. Growth hormone deficiency (GHD) is a condition where the pituitary gland does not produce enough growth hormone, leading to stunted growth in children and metabolic issues in adults. Nepexto is available in injectable solutions and pre-filled syringes or pens, and is distributed through hospitals, specialty clinics, retail pharmacies, and online pharmacies. It is used by various patient groups, including both adults and pediatric patients.
The nepexto market consists of sales of biologics, biosimilars, and recombinant proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing demand for cost-effective biologics alternatives, expansion of biosimilar markets in developing regions, supportive regulatory frameworks for biosimilar adoption, rising healthcare expenditure globally, growing preference for homecare and self-administered biologics. Major trends in the forecast period include a shift toward personalized medicine in biologics, growth of digital marketing and education for biosimilars, adoption of advanced drug delivery systems for biosimilars, strategic collaborations and partnerships in biosimilar development, and technological advancements in biologics manufacturing.
The growing prevalence of chronic diseases is expected to drive the expansion of the nepexto market. Chronic diseases are long-term conditions that typically last for more than three months and may require continuous medical attention or limit daily activities. The rise in chronic diseases can be attributed to factors such as aging populations, unhealthy lifestyles, and advancements in medical care, which help people with acute conditions live longer and, consequently, increase the occurrence of long-term health issues. Nepexto is used to treat chronic autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis, offering a cost-effective and accessible solution for managing these conditions over time. For example, in February 2024, the Centers for Disease Control and Prevention (CDC) reported that the prevalence of diagnosed arthritis in adults aged 18 and older was 18.9% in 2022, with women (21.5%) experiencing a higher incidence than men (16.1%). The prevalence of arthritis rises with age, from 3.6% in individuals aged 18-34 to 53.9% in those aged 75 and older. This increasing prevalence of chronic diseases is expected to support the growth of the nepexto market.
The rise in healthcare expenditure is anticipated to fuel the growth of the nepexto market. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including personal health care, preventive services, and public health activities aimed at improving health outcomes. This spending is increasing due to factors such as an aging population, chronic diseases, advancements in medical technology, high drug prices, inefficient payment models, and rising demand for healthcare services. Nepexto benefits from this increase in healthcare expenditure by providing a cost-effective treatment option for chronic autoimmune diseases, helping manage resource allocation while ensuring that patients have access to advanced biologic therapies. For example, in May 2024, the Office for National Statistics reported that healthcare expenditure in the UK rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Furthermore, long-term health and social care spending increased by 2.8% in real terms in 2022. As a result, rising healthcare expenditure is expected to drive the growth of the nepexto market.
A notable trend in the nepexto market is the development of biosimilars, such as etanercept, which are expected to provide a competitive advantage in the industry. Etanercept biosimilars are biological medications designed to replicate the original etanercept's structure, function, and therapeutic effects, often used to treat autoimmune conditions. For example, in May 2024, Lupin, an India-based pharmaceutical company, partnered with Sandoz, a Switzerland-based pharmaceutical company, to launch Rymti, an etanercept biosimilar, in Canada. The introduction of Rymti is expected to improve treatment options for patients with chronic inflammatory diseases while contributing to more sustainable healthcare solutions by providing a cost-effective alternative to existing therapies.
The key company operating in the nepexto market is Lupin Limited.
Europe was the largest region in the nepexto market in 2024. The regions covered in nepexto report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nepexto market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Nepexto is a biosimilar medication designed as an alternative treatment option for patients with autoimmune diseases. It is developed to closely match the reference biologic in terms of safety, efficacy, and quality. Nepexto is commonly used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, providing patients with a cost-effective and accessible therapeutic choice.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Nepexto include growth hormone deficiency, short stature due to idiopathic causes, Turner syndrome, and Prader-Willi syndrome. Growth hormone deficiency (GHD) is a condition where the pituitary gland does not produce enough growth hormone, leading to stunted growth in children and metabolic issues in adults. Nepexto is available in injectable solutions and pre-filled syringes or pens, and is distributed through hospitals, specialty clinics, retail pharmacies, and online pharmacies. It is used by various patient groups, including both adults and pediatric patients.
The nepexto market consists of sales of biologics, biosimilars, and recombinant proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Nepexto Market Characteristics4. Nepexto Market Trends And Strategies5. Nepexto Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Nepexto Pricing Analysis & Forecasts30. Global Nepexto Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Nepexto Market32. Recent Developments In The Nepexto Market
3. Nepexto Market Biologic Drug Characteristics
6. Global Nepexto Growth Analysis And Strategic Analysis Framework
8. Nepexto Market Segmentation
9. Global Nepexto Epidemiology Of Clinical Indications
10. Nepexto Market Regional And Country Analysis
11. Asia-Pacific Nepexto Market
12. China Nepexto Market
13. India Nepexto Market
14. Japan Nepexto Market
15. Australia Nepexto Market
16. South Korea Nepexto Market
17. Western Europe Nepexto Market
18. UK Nepexto Market
19. Germany Nepexto Market
20. France Nepexto Market
21. Eastern Europe Nepexto Market
22. North America Nepexto Market
23. USA Nepexto Market
24. Canada Nepexto Market
25. South America Nepexto Market
26. Middle East Nepexto Market
27. Africa Nepexto Market
28. Nepexto Market Competitive Landscape And Company Profiles
29. Global Nepexto Market Pipeline Analysis
33. Nepexto Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Nepexto Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on nepexto market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for nepexto ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nepexto market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Growth Hormone Deficiency; Short Stature Due To Idiopathic Causes; Turner Syndrome; Prader-Willi Syndrome2) By Formulation: Injectable Solution; Pre-Filled Syringes Or Pens
3) By Distribution Channel: Hospitals; Specialty Clinics; Retail Pharmacies; Online Pharmacies
4) By End User Patients: Adult Patients; Pediatric Patients
Key Companies Profiled: Lupin Limited
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Lupin Limited
